Roche’s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
6 June 2012 | By Roche
Data announced from the ADACTA study...
List view / Grid view
News
ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
6 June 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company have announced the results of AMPLE...
Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment
6 June 2012 | By Novartis
New data announced from two trials...
William Kaelin Jr. elected to Lilly Board of Directors
6 June 2012 | By Eli Lilly and Company
The Board of Directors of Eli Lilly and Company has elected William G. Kaelin Jr., M.D. as a new member...
Abbott presents Phase 3 study results for investigational use of HUMIRA®
6 June 2012 | By Abbott
First Phase 3 study to evaluate an anti-TNF in patients with non-radiographic axial spondyloarthritis...
Abbott announces 10-Year data evaluating HUMIRA® (Adalimumab)
6 June 2012 | By Abbott
Abbott announced results from two long-term, open-label studies...
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
New Phenomenex size exclusion columns for biomolecules deliver significant advancement in resolving power
6 June 2012 | By Phenomenex Inc
Phenomenex Inc., introduces Yarra™...
Catalent increased sterile fill-finish manufacturing capacity at its Research Triangle Park facility in NC
5 June 2012 | By Catalent Pharma Solutions
Completion of a newly renovated aseptic fill-finish manufacturing facility announced...
Merck receives complete response letter from U.S. FDA for investigational medicine ridaforolimusr
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
Abbott announces initiation of Phase 3 study of Elagolix in patients with endometriosis
5 June 2012 | By Abbott
Abbott have announced the initiation of a pivotal Phase 3 clinical trial...
Abbott introduces Ensure Clear™ to help adults fill dietary gap
5 June 2012 | By Abbott
One in three adults doesn’t obtain all of the daily nutrients they need to support optimal health...
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
Gerresheimer at CPhI China
4 June 2012 | By Gerresheimer
Gerresheimer will be showcasing innovative solutions for the pharma industry at CPHI China, which takes place in Shanghai from June 26 to 28...
GSK presents positive results for investigational BRAF and MEK inhibitors dabrafenib and trametinib at ASCO
4 June 2012 | By
Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints...
